Sort publications on year
-
OthersPublic Health and Epidemiology
The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report
HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.
Therapie ; 2020;52(4),420-426
-
Public Health and Epidemiology
The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report.
HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.
Digestive and Liver Disease ; 2019
-
Pharmaco - Epidemiology
Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.
BARBUT F, GALPERINE T, VANHEMS P, LE MONNIER A, DURAND-GASSELIN B, CANIS F, JEANBAT V, DUBURCQ A, ALAMI S, BENSOUSSAN C, FAGNANI F.
Health Qual Life Outcomes ; 2019;17(1);6
-
Pharmaco-Economics
Etude pharmaco-économique sur la prise en charge du reflux gastro-oesophagien en France en 2005 en médecine générale
MOULY S, CHARLEMAGNE A, LE JEUNNE PH, FAGNANI F
Presse Med ; 37:1397-1406
-
Pharmaco - Epidemiology
Irritable bowel syndrome in France : quality of life, medical management, and costs : the Encoli Study
BRUN-STRANG C, DAPOIGNY M, LAFUMA A, WAINSTEN JP, FAGNANI F
Eur J Gastroenterol Hepatol ; 19(12):1097-1103
-
Pharmaco - Epidemiology
Enquête nationale sur les pratiques de prophylaxie des hémorragies gastroduodénales en réanimation
DHOTE R, DETOURNAY B, SLAMA A, HAMEL L, BIGARD MA, BOLLAERT PE, COLIN R, FAGON JY, LE GALL JR, RAPHAEL JC
Réanimation Urgences ; 2000;9(7):550-554
-
Biometry and database analysis
Excess mortality between 2007 and 2014 among patients with Clostridium difficile infection: a French health insurance database analysis
BARBUT F, BOUEE S, LONGEPIERRE L, GOLDBERG M, BENSOUSSAN C, LEVY-BACHELOT L
J Hosp Infect ; 2017;98(1):21-28
-
Pharmaco - Epidemiology
Infliximab Paediatric Crohn’s Disease Educational Plan : A European, Cross-Sectional, Multicentre Evaluation
ARANA A, ALLEN S, BURKOWITZ J, FANTONI V, GHATNEKAR O, RICO MT, VANHAVERBEKE N, WENTWORTH CE, BROSA M, ARELLANO F
Drug Saf ; 2010;33(6):489-501